AIV Logo AIV Assistant

Loading...

 Logo Novavax, Inc. - NVAX 6.88 USD

EPS
-2.18
Beta
2.09
Target Price
16.00 USD

6.880 USD

6.880 USD

Daily: +0.00%
Key Metrics

Earnings date: Feb. 26, 2025

EPS: -2.18

Book Value: -3.29

% Insiders: 4.452%

Growth

Revenue Growth: -0.55%

Earnings Growth: 0.71%

Estimates

Forward P/E: 24.30

Forward EPS: -0.16

Target Mean Price: 16.00

 Logo About Novavax, Inc. - (NVAX)

Country: United States

Sector: Health Care

Website: http://www.novavax.com

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Exchange Ticker
FRA (Germany) NVV1.F
MEX (Mexico) NVAX.MX
None US6700024010
NMS (United States) NVAX

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
May 10, 2019 0.05
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion